Quick Answer
Cogent Biosciences, Inc. reported Research And Development Expense of $269.78 million for the year ending 2025.
- Cogent Biosciences, Inc. showed an increase of +16.0% in Research And Development Expense from 2024 to 2025.
- This data is from Cogent Biosciences, Inc.'s annual report (Form 10-K), filed with the SEC on February 17, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 9 years of available data (2017 to 2025), Cogent Biosciences, Inc.'s Research And Development Expense has grown by 804.3%.
- Historical annual values: Fiscal year 2025: $269.78 million | Fiscal year 2024: $232.66 million | Fiscal year 2023: $173.76 million | Fiscal year 2022: $121.63 million | Fiscal year 2021: $55.91 million | Fiscal year 2020: $25.74 million | Fiscal year 2019: $43.71 million | Fiscal year 2018: $38.29 million | Fiscal year 2017: $29.83 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: